Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis

Hedin, Charlotte Rose Hawkey ; Sado, Gina ; Ndegwa, Nelson ; Lytvyak, Ellina ; Mason, Andrew ; Montano-Loza, Aldo ; Gerussi, Alessio ; Saffioti, Francesca ; Thorburn, Douglas and Nilsson, Emma LU , et al. (2020) In Clinical Gastroenterology and Hepatology 18(10). p.2-2304
Abstract

Background & Aims: Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC and IBD, and their efficacy in treatment of IBD. Methods: We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical... (More)

Background & Aims: Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC and IBD, and their efficacy in treatment of IBD. Methods: We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical response, as determined by the treating clinician or measurements of fecal calprotectin. Remission was defined more stringently as endoscopic mucosal healing. We used linear regression analysis to identify factors associated significantly with level of ALP during anti-TNF therapy. Results: Anti-TNF treatment produced a response of IBD in 48% of patients and remission of IBD in 23%. There was no difference in PSC symptom frequency before or after drug exposure. The most common reasons for anti-TNF discontinuation were primary nonresponse of IBD (17%) and side effects (18%). At 3 months, infliximab-treated patients had a median reduction in serum level of ALP of 4% (interquartile range, reduction of 25% to increase of 19%) compared with a median 15% reduction in ALP in adalimumab-treated patients (interquartile range, reduction of 29% to reduction of 4%; P =.035). Factors associated with lower ALP were normal ALP at baseline (P <.01), treatment with adalimumab (P =.090), and treatment in Europe (P =.083). Conclusions: In a retrospective analysis of 141 patients with PSC and IBD, anti-TNF agents were moderately effective and were not associated with exacerbation of PSC symptoms or specific side effects. Prospective studies are needed to investigate the association between use of adalimumab and reduced serum levels of ALP further.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Anti-Inflammatory, Hepatic, Intestine, Liver Transplantation
in
Clinical Gastroenterology and Hepatology
volume
18
issue
10
pages
2 - 2304
publisher
Elsevier
external identifiers
  • pmid:32068151
  • scopus:85082932202
ISSN
1542-3565
DOI
10.1016/j.cgh.2020.02.014
language
English
LU publication?
yes
id
4f5a16a9-bb9a-47cd-9c23-f693ec016e9f
date added to LUP
2021-01-08 13:36:15
date last changed
2024-05-01 23:53:51
@article{4f5a16a9-bb9a-47cd-9c23-f693ec016e9f,
  abstract     = {{<p>Background &amp; Aims: Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC and IBD, and their efficacy in treatment of IBD. Methods: We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical response, as determined by the treating clinician or measurements of fecal calprotectin. Remission was defined more stringently as endoscopic mucosal healing. We used linear regression analysis to identify factors associated significantly with level of ALP during anti-TNF therapy. Results: Anti-TNF treatment produced a response of IBD in 48% of patients and remission of IBD in 23%. There was no difference in PSC symptom frequency before or after drug exposure. The most common reasons for anti-TNF discontinuation were primary nonresponse of IBD (17%) and side effects (18%). At 3 months, infliximab-treated patients had a median reduction in serum level of ALP of 4% (interquartile range, reduction of 25% to increase of 19%) compared with a median 15% reduction in ALP in adalimumab-treated patients (interquartile range, reduction of 29% to reduction of 4%; P =.035). Factors associated with lower ALP were normal ALP at baseline (P &lt;.01), treatment with adalimumab (P =.090), and treatment in Europe (P =.083). Conclusions: In a retrospective analysis of 141 patients with PSC and IBD, anti-TNF agents were moderately effective and were not associated with exacerbation of PSC symptoms or specific side effects. Prospective studies are needed to investigate the association between use of adalimumab and reduced serum levels of ALP further.</p>}},
  author       = {{Hedin, Charlotte Rose Hawkey and Sado, Gina and Ndegwa, Nelson and Lytvyak, Ellina and Mason, Andrew and Montano-Loza, Aldo and Gerussi, Alessio and Saffioti, Francesca and Thorburn, Douglas and Nilsson, Emma and Larsson, Geir and Moum, Bjørn A. and van Munster, Kim N. and Ponsioen, Cyriel Y. and Levy, Cynthia and Nogueira, Nicholas F. and Bowlus, Christopher L. and Gotlieb, Neta and Shibolet, Oren and Lynch, Kate D. and Chapman, Roger W. and Rupp, Christian and Vesterhus, Mette and Jørgensen, Kristin K. and Rorsman, Fredrik and Schramm, Christoph and Sabino, João and Vermeire, Severine and Zago, Alessandra and Cazzagon, Nora and Marschall, Hanns Ulrich and Ytting, Henriette and Ben Belkacem, Karima and Chazouilleres, Olivier and Almer, Sven and Bergquist, Annika}},
  issn         = {{1542-3565}},
  keywords     = {{Anti-Inflammatory; Hepatic; Intestine; Liver Transplantation}},
  language     = {{eng}},
  number       = {{10}},
  pages        = {{2--2304}},
  publisher    = {{Elsevier}},
  series       = {{Clinical Gastroenterology and Hepatology}},
  title        = {{Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis}},
  url          = {{http://dx.doi.org/10.1016/j.cgh.2020.02.014}},
  doi          = {{10.1016/j.cgh.2020.02.014}},
  volume       = {{18}},
  year         = {{2020}},
}